Skip to contentL
Lineage Cell Therapeutics, Inc.
L
LCTXLineage Cell Therapeutics, Inc. Q3 2014 · 10-Q
Revenue$960.00K$960.00K+89.2% vs Q3 2013 Net Income-$8.27M-$8.27MN/M vs Q3 2013 EPS Diluted-$0.12-$0.12N/M vs Q3 2013 Gross Profit$960,202+89.2% Operating Income
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lineage Cell Therapeutics, Inc. · CIK 876343 · Engraved from SEC EDGAR
Operating Cash Flowderived-$8,608,759N/M Free Cash Flowderived-$8,701,229N/M Margins · derivedGross margin100.0%+0.0 pt vs Q3 2013
Operating margin-1264.3%+746.4 pt vs Q3 2013
Net margin-861.2%+913.2 pt vs Q3 2013
ended Sep 30, 2014 · filed Nov 7, 2014 · 38 d after period end